LXRX Lexicon Pharmaceuticals Inc.

3.2
-0.04  -1%
Previous Close 3.24
Open 3.24
Price To Book -5.25
Market Cap 340,070,166
Shares 106,271,927
Volume 1,280,188
Short Ratio
Av. Daily Volume 2,366,399
Stock charts supplied by TradingView

NewsSee all news

  1. Lexicon Pharmaceuticals Announces Poster Presentations at the NANETS Annual Multidisciplinary NET Medical Symposium

    THE WOODLANDS, Texas, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), announced today that data from five posters highlighting XERMELO® (telotristat ethyl) will be presented at the

  2. Lexicon Pharmaceuticals Announces Termination of Alliance and Settlement With Sanofi

    THE WOODLANDS, Texas, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today announced the termination of its alliance with Sanofi for the development and commercialization of ZynquistaTM

  3. Lexicon Pharmaceuticals to Present Sotagliflozin Clinical Data at the European Association for the Study of Diabetes 55th Annual Meeting

    THE WOODLANDS, Texas, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today announced that clinical data for ZynquistaTM (sotagliflozin) will be presented at the upcoming European

  4. Lexicon Pharmaceuticals To Present At Upcoming Investor Conference

    THE WOODLANDS, Texas, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative Affairs and Chief

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data released September 9, 2016 met primary endpoint. Data from second trial released December 21, 2016 - primary endpoint met. Data from third trial also met primary endpoint - June 9, 2017.
Sotagliflozin
Type 1 Diabetes
Phase 2 trial did not meet primary endpoint.
Sotagliflozin
Type 1 Diabetes
CRL issued March 22, 2019.
Sotagliflozin
Type 1 Diabetes
Approved February 28, 2017.
Telotristat etiprate (XERMELO)
Carcinoid Syndrome
SNY informed LXRX July 26, 2019 that it plans to terminate its agreement following insufficient efficacy across three Phase 3 trials.
Sotagliflozin
Type 2 Diabetes
Phase 1b top-line data due 2H 2019.
LX9211
Neuropathic pain
Phase 2a initiation of dosing announced March 15, 2019. Top-line data due 2020.
Telotristat ethyl - TELE-ABC
Biliary tract cancer (BTC)

Latest News

  1. Lexicon Pharmaceuticals Announces Poster Presentations at the NANETS Annual Multidisciplinary NET Medical Symposium

    THE WOODLANDS, Texas, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), announced today that data from five posters highlighting XERMELO® (telotristat ethyl) will be presented at the

  2. Lexicon Pharmaceuticals Announces Termination of Alliance and Settlement With Sanofi

    THE WOODLANDS, Texas, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today announced the termination of its alliance with Sanofi for the development and commercialization of ZynquistaTM

  3. Lexicon Pharmaceuticals to Present Sotagliflozin Clinical Data at the European Association for the Study of Diabetes 55th Annual Meeting

    THE WOODLANDS, Texas, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today announced that clinical data for ZynquistaTM (sotagliflozin) will be presented at the upcoming European

  4. Lexicon Pharmaceuticals To Present At Upcoming Investor Conference

    THE WOODLANDS, Texas, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative Affairs and Chief